Member Info for 2017andonwards

Building desire, providing detail, explaining heritage and showing how they want to interact with their customers https://binged.it/2gQUmQ7 All through the power of film, simple to understand easy to share with friends. Who doesn't appreciate that?

Jason2 said 'At the shareholders � meeting in May the chairman stated the board had heard loud and clear the message that there was widespread dissatisfaction with the share price performance and that this would be taken on board.' That is quite correct, he did. He even asked for that line of questioning to stop and for shareholders to move on because as you say, the board heard that message loud and clear. I suspect the story is good, but they do not understand how to tell their story to investors and furthermore, they have not as yet delivered anything in this respect outside of the RNS channel. An interim profit didn't move the share price, so why will an annual profit move the share price. The Chairman stepping down and making way is great news, but something else needs to change. Can you imagine Eden not extolling the virtues of 3AEY to the industry players and thus not selling their product? No! So why don't Eden extol the virtues of the Company to the investment community so that they can make a reasoned assessment about making an investment in today's and tomorrows share price. Can you imagine Rolls Royce engineering and designing the most beautiful and expensive car and then not selling to car buyers all of its features and benefits and creating purchasing desire around the same? No Do you want one? https://www.rolls-roycemotorcars.com/en-GB/dawn-overview.html Crazy!

ash666 said "From articles written etc, I get the impression that the cynical farmers have just been doing small scale testing of the product this year". So that impression needs correcting by the Company, doesn't it! They did say in the Portugal approval RNS that they had "already had significant commercial success". So if you and other missed or misinterpreted this, then the Company needs to be more expansive and detailed so that all existing shareholders clearly understand the Company's progress and current state of play. People take far more in visually than in the written word. So much gets lost and misunderstood in the written word. Eden and Powerscourt should put this right.

Funny how we are stuck in this 10-11p price range! Dips down to the lower point today and then in pops enough orders to prop it up again. Gets supressed at the end of the range two, certainly up to 13p. Why is it not trading outside this range aside of a dismal number of trades.

Tonypeters, I didn't say they did take account of BB's. What I said was Eden needs to be more communicative because the RNS channel in isolation is not encouraging new investment from anywhere. It is a fact that the shares are in effect static for the long-term investor over this past two years even allowing for Eden's progress. That cannot be correct!!!

The Company to me appears fundamentally disconnected from its investors, specifically its private investors. What efforts and executions has the Company made this year, specifically targeted at educating and reassuring PI's? None that I can recall. Eden has executed two financial and regulatory PR events if we can call it PR, namely the interims for 2017 and the full year report for 2016. There has been no other direct effort to engage shareholders to unravel and detail the story and its subsequent success. What indicators do we have that there has been success? 1) A small operating profit in the interims, but no forward statements as to likely success over the coming six months, even though the Company is selling direct and knows their sales numbers to distributors. Growers in-field success can be reported later. 2) The introduction of the new Chairman in waiting 3) �3.6 million cash in the bank although �2.8 million of that comes from the placing in the summer and an upfront payment of �600,000 from Sipcam I would ask how many PI's are reading the financial reports and is this really a driver for them? Does the Company need to put in greater effort and layers of communication to raise the profile of the Company? Should Eden be using other methods outside the regulatory channel to communicate regulatory news so that it is received and understood in a more palatable way? Would the above drive greater interest in Eden and therefore more impetus into the share price? Would that interest be further shared with others thus doubling down? Would Eden then be seen as more approachable and a more interesting investment opportunity? Eden has said in the past they will make a greater effort to be more communicative! When is that going to happen because the market gauged by share trades and discussion isn't interested in investing in Eden in its current form.

Why can't we edit these posts!!!! Should have read "They will also be entrusted with selling the investment case in Eden, but with a market cap of around �23 million their hands are tied."

Cont'd 5) "Leadership" Source http://www.edenresearch.com/about-us/leadership Leadership comes in many forms and one of the requirements of a listed company is to deliver value through the share price to investors. At the moment, Eden appears to have either no idea how to do this or no apparent enthusiasm to do this. This is a huge mistake on their part and the share price is the measurable product as to the appeal and the opportunity of Eden Research. Share prices should move in line with commercial success, even more so with "significant commercial success!" To facilitate a market cap that lags behind commercial success when there is no reason to do so and when markets at large are doing well is remiss Financial PR firms specialise in, among other things, "crisis management". Powerscourt claims on their website to be the "the City's pre-eminent communications adviser on reputational and contentious matters". In terms of corporate positioning they state "You have an interesting story to tell: our job is to help you identify it, express it and distribute it". Well as far as I can see, Eden very much has a reputational issue through their share price. The story that is out there is not aligned to value and this is damaging the investment case in Eden Research. The share price and actions of investors clearly indicate this and has done so over the last few years. Look at how many shares were traded the day Eden announced the Eastman deal. Then look at Friday's interims announcement, first ever profit and look at the shares traded and the resulting price action. Investors cannot see the investment case. I believe it is there in the product, but management and their advisers are not paying attention to their invested and potential investor audience. Address the retail audience and the institutional investors will take care of themselves. If in the coming years they wish to benefit from pay, bonuses and share options then they should address the share price now and keep a constant focus on ensuring this is aligned to commercial success, so that their pay, bonuses and share options are well deserved. This is what everyone wants!

Jason2 All of that is quite correct. If Eden had products that sold every day of the month and were not seasonal then waiting for the year end results would be palatable. Eden's 3AEY, its only on sale commercial product at this moment in time will have sold through now for 2017. Hence the need for a trading update RNS to advise the market. I do believe that if a company is in receipt of information that will materially affect the share price then under LSE regulation they are required to share that information with the market. So if that is so, we could assume that sales have been poor and there is no need to advise the market OR if sales have been tremendous, (Eden has alluded to the same with their statement on significant commercial success) then one could easily presume that there is news to share which will affect the share price in a positive way. It would be a mistake to hold this information back until December the 31st or beyond when the accounts are published. Shore Capital's job is simply to ensure that Eden and other companies adhere to the regulations set down by the London Stock Exchange. They will also be entrusted with selling the investment case in Eden, but with a market cap of around �223 million their hands are tied. Powerscourt have been brought in to replace Walbrook PR. No point in doing that unless you have a plan in place, to execute, that is for the benefit of investors. Has Powerscourt set out a plan of action over the coming weeks and months for the Eden brand and will Powerscourt go beyond a PR remit and ensure investor communciations is executed to enlarge the share register and educate people to recognise the value of Eden today and in the future? This could now be considered a matter of urgency. Financial PR companies specialise in financial matters and rarely do they get involved with private investors/retail investors who are the most important factor in small cap AIM listed companies. Why? Well they drive the price and bring down the cost of capital to these companies and then, when the price is right, the broker can start selling the Eden investment proposition with success. The latter doesn't really happen until the former has been achieved. Eden's view of themselves:- 1) "Our vision is to be the leader in sustainable bioactive products enabled or enhanced by our novel encapsulation and delivery technologies" Source: http://www.edenresearch.com/investors/investment-case 2) "Our customers are global and regional industry leaders who wish to add value to their products by" Source http://www.edenresearch.com/our-technology 3) Our customers and partners Source http://www.edenresearch.com/about-us/our-partnerships 4) "Our market" Source http://www.edenresearch.com/about-us/our-market Are Eden really going for this market or a share thereof or subset. They should add clarity because I am certain they are not going after these topline n

The market, you and me in the case of Eden's share register, needs clarity. The grape season is over in Europe and a trading update to bridge the gap between the 30th June and now would be most helpful and specifically relevant. Among many other things, Eden needs to inform the market of total product sales, because this is seasonal and in doing so, this will help bridge the gap between statements like "already had significant commercial success" and a stumbling share price relative to that success. A company's share price should reflect it's performance. Edens, for a now profitable industrial biotech, is not doing that and so the company and its advisers have a duty of care to ensure the two are more closely matched. What are they going to do in the immediate future to ensure that situation is rectified?

No ash, we haven't. Question is, if it is that significant, why is it hidden as a small statement in this RNS????

Courtesy of supersonico on advfn https://globenewswire.com/news-release/2017/05/12/984425/0/en/Global-Bio-pesticides-Market-2017-2022-Bio-insecticide-Bio-fungicide-Bio-herbicide-Bio-nematicide-Others.html

Taken from advfn, not my research

https://dailynewsegypt.com/2017/05/23/natural-fungicide-could-restore-french-winemaking-glory “I think it’s the future for agriculture in the world.” "It’s hoped Mevalone, which has just been approved for use in France and several other European countries, could help France recover its world position as the world’s biggest wine producer." "Some believe Mevalone could revolutionize grape-growing around the world."

Sain@vision No other deals? Did you miss the global Eastman deal, expected to be worth more than the 3AEY deals!

The product has a shelf life of 2 years, so if Sipcam et al didn't sell out in Europe this year, for whatever reason, the product will not go to waste. This shouldn't be confused with sales of 3 AEY by Eden to its agents which will deliver the results in Eden's P and L.

Agreed

"Again, prevention is better than cure. Plan to hit hard and hit early, before any infection becomes established." I wonder if Sipcam and Sumi have been selling 3AEY as a preventative measure and to be applied accordingly for further insurance of the farmers grape crop? Let's hope so!

Today's paper http://www.dailymail.co.uk/health/article-4710590/Why-buy-organic-strawberries.html?ito=email_share_article-top Strawberry Market http://www.octofrost.com/news-room/a-glimpse-into-the-fresh-and-frozen-strawberry-markets And strawberries was the first picture on the inside of the 2016 accounts. I cannot remember the commentary. A recent Sipcam press article said they would be looking to the US and China in their relationship with Eden. Could this mean strawberries too?!

Those two 50,000 share 'sells' are in fact share 'buys'. It is astonishing that they are misrepresented which may dent the confidence of some, but in the least, create the wrong impression.